Home
Contact Us
facebook
twitter
linkedin
menu
Menu
About Us
Show sub menu
arrow-down
Mission
Members
Board of Directors
Staff
Work at ACLA
2025 Annual Meeting
Economic Impact
Issues
Show sub menu
arrow-down
PAMA Reform
Public Health Preparedness and Infrastructure
Regulatory Issues
Reimbursement & Coverage
Value of Clinical Labs: The Power of Knowing
Take Action
Newsroom
Show sub menu
arrow-down
ACLA Blog
ACLA Press Releases
Comments and Letters
Spotlight on Lab Professionals
All News
COVID-19
Member Resources
Show sub menu
arrow-down
ACLA’s 2025 Advocacy Agenda
CPT Committee
Close Menu
cross
Home
Contact Us
About Us
Show sub menu
arrow-down
Mission
Members
Board of Directors
Staff
Work at ACLA
2025 Annual Meeting
Economic Impact
Issues
Show sub menu
arrow-down
PAMA Reform
Public Health Preparedness and Infrastructure
Regulatory Issues
Reimbursement & Coverage
Value of Clinical Labs: The Power of Knowing
Take Action
Newsroom
Show sub menu
arrow-down
ACLA Blog
ACLA Press Releases
Comments and Letters
Spotlight on Lab Professionals
All News
COVID-19
Member Resources
Show sub menu
arrow-down
ACLA’s 2025 Advocacy Agenda
CPT Committee
Home
|
All News
|
Comments and Letters
|
ACLA Comment Letter on Reconsideration Request for New Therapeutic Drug and Molecular Pathology CPT Codes
ACLA Comment Letter on Reconsideration Request for New Therapeutic Drug and Molecular Pathology CPT Codes
January 20, 2021
Categories:
Comments and Letters
,
Issues
,
Reimbursement and Coverage
Download (PDF, 219KB)
Print page / Save as PDF
